ArticleCell communication and signaling : CCS2025
Adipocyte/Tumor cell crosstalk via IGF-1/TXNIP axis promotes malignancy and endocrine resistance in breast cancer.
Article in Cell communication and signaling : CCS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Patient-Derived Organoids in Gastrointestinal Disease: Current Applications, Limitations, and Future Perspectives.International journal of molecular sciences · 2026Review
- Effect of bariatric surgery timing on breast cancer incidence: Real-world evidence from TriNetX.Breast (Edinburgh, Scotland) · 2026Observational
- Circulating Thioredoxin 1 as an Adjunct to Mammography for Breast Cancer Detection: A Multicenter Clinical Validation Study.Cancers · 2026Article
- Insulin Resistance as a Systemic Metabolic Risk State for Cancer: Mechanisms, Biomarkers, and Prevention.International journal of molecular sciences · 2026Review
- Article
- Patient-derived organoids in functional precision oncology: from experimental models to clinical decision-making.Frontiers in endocrinology · 2026Review
- Adipocyte-derived estrogen signaling influences TROP2 expression in ERα-positive breast cancer.Frontiers in endocrinology · 2026Article
- From benchside avatars to bedside breakthroughs: Patient-derived organoids in the new era of cancer immunotherapy.Translational oncology · 2026Review
- The association between diabetes and head and neck squamous cell carcinoma: evidence from clinical cohort and bioinformatics analyses.Frontiers in genetics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
Abstract
backgroundDespite significant improvements in the outcome of Estrogen Receptor (ER) α-positive breast cancer (BC) following the use of endocrine therapies, resistance remains a major challenge. Clinical studies proved that obesity, in addition to promote BC progression, is associated with a reduced efficacy to these treatments, but mechanisms remain unclear.
methodsWe used co-culture systems followed by validation through an ‘ex vivo’ model of human mammary obese (Ob) adipocytes and obese endocrine-resistant metastatic Patient-Derived Organoids (PDOs). Transcriptomics with MixOmics-MINT and MetaCore Functional Tools along with lentiviral and pharmacological approaches provide insights into mechanisms. Clinical relevance was investigated using public datasets, transcriptome-based (n = 375), and immunohistochemistry-based (n = 65) evaluations.
resultsIn a model of co-culture, we demonstrated that conditioned media (CM) released by 3T3-L1A adipocytes reduced the sensitivity of parental MCF-7 BC cells to the inhibitory effects of Tamoxifen (Tam) on growth, motility and invasion and significantly increased the proliferative, motile and invasive phenotype of Tam-resistant (TR) BC cells. Transcriptomics identified TXNIP (Thioredoxin-interacting protein), a known tumor suppressor gene, as a network central hub, that was significantly down-regulated in CM-treated MCF-7 and TR cells. Accordingly, TXNIP expression was negatively correlated with Body Mass Index (BMI) in BC patients. Lentiviral TXNIP overexpression and pharmacological induction of TXNIP (i.e. SAHA) or the blockade of insulin-like growth factor-I (IGF-1) signaling, an obesity hallmark able to affect TXNIP expression, reversed CM-mediated effects. TXNIP down-regulation, proliferation and motility in TR cells were exacerbated by CM derived from Ob 3T3-L1A, and combination of an IGF-1 inhibitor and SAHA abrogated Ob-CM activities. Results were also validated in aromatase inhibitor-resistant BC cells. The effectiveness of IGF-1/TXNIP axis inhibition was confirmed using an ‘ex vivo’ model of human mammary obese adipocytes and PDO models. Finally, retrospective analyses demonstrated that an IGF-1high/TXNIPlow signature was correlated with poorer survival in endocrine-treated BC patients.
conclusionsIn conclusion, our study sheds new light on adipocyte/BC cell crosstalk, underscoring the potential of targeting IGF-1/TXNIP axis to block this harmful connection, especially in the context of obesity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.